Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Julie Renee Brahmer, M.D.
Interim director, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus)
Associate Professor of Oncology
Expertise: Clinical Trials, Lung Cancer, Medical Oncology, Mesothelioma
Research Interests: Development of anti-PD-1 antibodies; Drug development for thoracic malignancies and immunotherapy
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program and Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network.
Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins.
Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma.
Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies.
She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation.
- Interim director, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus)
- Director, Thoracic Oncology
- Associate Professor of Oncology
Centers & Institutes
- MD, University of Nebraska Medical Center - GME (1993)
- The University of Utah / Internal Medicine (1997)
- Johns Hopkins University School of Medicine / Oncology (2000)
- American Board of Internal Medicine / Medical Oncology (1999, 2010)
Research & Publications
Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma at SKCCC. She is in charge organizing the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. She is also a part of the oncology pain team headed by Dr. Stuart Grossman.
Clinical Trial KeywordsPhase 1, mesothelioma, lung cancer
Selected PublicationsView all on Pubmed
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, Activity and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med 2012; 366(26):2443-54.
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 2012; 366(26):2455-65.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MA, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. A Phase I Study of Single-Agent Anti-PD1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics and Immunological Correlates. J Clin Oncol, 2010; 28(19):3167-75.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares, L, Reck M, Baudelet,C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2);123-35.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39.
Activities & Honors
Videos & Media
Recent News Articles and Media Coverage
- Finding Your Best Treatment Options for Lung Cancer" Webinar, featuring Drs. Richard Battafarano and Julie Brahmer. Recorded Nov. 9, 2015.
- Breakthroughs in Cancer Immunotherapy Webinar: Immunotherapy for Lung Cancer: What Patients Need to Know. In a one-hour seminar, hosted by the Cancer Research Institute on Aug. 21, 2015, Dr. Brahmer discussed the latest research and current immunotherapies for patients with lung cancer.